98%
921
2 minutes
20
Background: The incidence of adult-onset atopic dermatitis (AOAD) is increasing. However, the unique characteristics of AOAD compared to pediatric-onset AD persisting into adulthood (POAD) are underexplored, hampering the development of targeted-therapeutics for this growing population. We thus assessed the profile of AOAD in skin and blood compared to that of POAD.
Methods: We collected skin biopsies and blood from adults with AOAD, POAD, and healthy controls (n = 15 in each group). Skin samples were analyzed by RNA sequencing, qRT-PCR, and immunohistochemistry, and Olink Proseek multiplex assay was used to identify the serum proteomic profile.
Results: Compared to healthy controls, both AOAD and POAD showed cutaneous immune and barrier dysregulations with a shared Th2/Th22 hyperactivation. Overall, POAD showed greater inflammation in lesional skin, with more prominent expression of Th2/Th17/Th22 markers (CCL17/22, S100A8/9, IL-36A, PI3/Elafin, DEFB4) in POAD compared to AOAD (p-value < .05). In contrast, higher Th1-(IFN-γ, IL-2, IL-15, CCL5) upregulation and Th1-skewing were seen in AOAD. The epidermal barrier was also more compromised in POAD, with greater epidermal hyperplasia and lower expression of markers related to terminal differentiation, lipids, and cell adhesion. In parallel with increased rates of cardiovascular comorbidities, AOAD demonstrated many more significantly dysregulated proteins in serum (n = 148) compared to POAD (n = 86), including pro-inflammatory and cardiovascular-risk markers. Th1-related products showed significant correlations between their skin and blood expressions only in AOAD subjects.
Conclusion: Age-of-onset delineates two distinct endophenotypes in adult AD potentially suggesting the need for broader (beyond Th2) therapeutic targeting in AOAD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.15741 | DOI Listing |
J Dermatolog Treat
December 2025
Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Background: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
Objectives: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.
Methods: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed.
J Allergy Clin Immunol Pract
September 2025
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Studies have described sex differences in childhood asthma, allergy, and atopic dermatitis, but the development and clinical phenotype of these differences remain poorly understood.
Objective: To characterize sex differences in atopic disease throughout childhood and study the potential role of sex-steroid metabolites.
Methods: We examined sex differences in asthma, allergy, and atopic dermatitis using longitudinal generalized estimating equation models in the COPSAC (n=411) and COPSAC (n=700) birth cohorts.
J Allergy Clin Immunol
September 2025
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China. Electronic address:
Background: Keratinocytes form the skin's first line of defense, not only serving as a physical barrier but also actively communicating with immune cells and sensory neurons.
Objective: To elucidate the molecular mechanisms by which keratinocytes contribute to barrier dysfunction and neuroimmune activation in atopic dermatitis (AD).
Methods: CB2R expression was assessed by RNA-seq, qRT-PCR, RNAscope fluorescence, and western blot.
Dermatitis
September 2025
From the Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
There are limited data regarding photopatch testing (PPT) in Israel. To investigate the prevalence of positive reactions and concurrent diagnosis of patients that underwent PPT in a single center in Israel. Retrospective cohort study that included all patients that were suspected of having contact dermatitis and underwent patch testing with the European baseline series (EBS) and additionally were selectively PPT with the Scandinavian/European baseline photopatch series in a tertiary medical center in Israel (2009-2023).
View Article and Find Full Text PDFDermatitis
September 2025
From the Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain.
Atopic dermatitis (AD) is a common chronic inflammatory skin condition influenced by genetic and environmental factors. The role of lifestyle on AD remains unclear. This study explores the association between adherence to the Mediterranean diet (MD), physical activity (PA) levels, and AD severity.
View Article and Find Full Text PDF